Menu

Redirecting Gene Therapy Restores Sight

By targeting rhodopsin genes to neurons, scientists help blind mice see.

Aug 17, 2015
Amanda B. Keener

WIKIMEDIA, SANTIAGO RAMON Y CAJAL

A team of researchers at the University of Manchester enabled blind mice with advanced retinal degeneration to see by delivering the gene for a light-sensing protein into nervous cells within their retinas, according to a study published last month (July 30) in Current Biology.

“This is the most effective example yet of the use of genetic therapy to treat advanced retinal degeneration,” Robin Ali, who studies gene therapy at University College London and was not involved in the work told New Scientist.

Researchers have previously used virus-based gene therapies to replace lost or defective genes in rods and cones, the photoreceptor cells of the retina. But for the present study, the team set its sights on ganglion and bipolar cells, which transduce signals from rods and cones into electrical signals sent to the brain. By delivering the gene for the light-sensing pigment, rhodopsin to these cells they bypassed the need for rods and cones. Doing so enabled the treated mice to respond to visual stimuli, such as a video of an owl swooping.

“The treated mice could discriminate black and white bars, but only ones that were 10 times thicker than what sighted mice could see,” Robert Lucas, study coauthor and geneticist at the University of Manchester told New Scientist.

Lucas added that the virus they used to deliver the gene is approved for use in humans, which means trials in humans could begin in the next five years.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!